Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity DOI Creative Commons
Isabella Zaffina, Maria Chiara Pelle, Giuseppe Armentaro

и другие.

Frontiers in Endocrinology, Год журнала: 2023, Номер 14

Опубликована: Фев. 22, 2023

The occurrence of obesity is an increasing issue worldwide, especially in industrialized countries. Weight loss important both to treat and prevent the development complications. Currently, several drugs are used obesity, but their efficacy modest. Thus, new anti-obesity treatments needed. Recently, there has been increased interest incretins that combine body-weight-lowering glucose-lowering effects. Therefore, a drug simultaneously coactivates glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) glucagon-like peptide-1 (GLP-1R) developed. Tirzepatide, first this class, improves glycemic control by insulin sensitivity lipid metabolism as well reducing body weight. Combining activation two receptors, greater improvement β-cell function offers more effective treatment diabetes with fewer adverse effects than selective GLP-1R agonists. In present review, we discuss progress use GIPR coagonists review literature from vitro studies, animal human trials, highlighting synergistic mechanisms tirzepatide.

Язык: Английский

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy DOI Creative Commons

Zhikai Zheng,

Zong Yao,

Yiyang Ma

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Сен. 18, 2024

The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and found primarily on surfaces various cell types within human body. This specifically interacts with GLP-1, key hormone that plays an integral role in regulating blood glucose levels, lipid metabolism, several other crucial biological functions. In recent years, GLP-1 medications have become focal point medical community due to their innovative treatment mechanisms, significant therapeutic efficacy, broad development prospects. article thoroughly traces developmental milestones drugs, from initial discovery clinical application, detailing evolution diverse along distinct pharmacological properties. Additionally, this paper explores potential applications agonists (GLP-1RAs) fields such neuroprotection, anti-infection measures, reduction inflammation, enhancement cardiovascular function. It provides in-depth assessment effectiveness GLP-1RAs across multiple body systems-including nervous, cardiovascular, musculoskeletal, digestive systems. includes integrating latest trial data delving into signaling pathways mechanisms. primary goal emphasize extensive benefits using treating spectrum diseases, obesity, non-alcoholic fatty liver disease (NAFLD), neurodegenerative musculoskeletal forms cancer. ongoing new indications for drugs offers promising prospects further expanding interventions, showcasing field.

Язык: Английский

Процитировано

140
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach DOI Creative Commons

Jingyue Wang,

Quanwei Wang, Xinyu Yang

и другие.

Frontiers in Endocrinology, Год журнала: 2023, Номер 14

Опубликована: Фев. 1, 2023

Obesity is a complex disease characterized by excessive fat accumulation which caused genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat people’s health lives, increasing public care expenses. Evidence from previous studies show that weight loss can significantly reduce risk of obesity-related complications chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery prescription drug treatment are major interventions used help people lose weight. Among them, anti-obesity drugs have high compliance rates cause noticeable short-term effects reducing obese levels. However, given safety or effectiveness concerns drugs, many currently limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists group targets incretin hormone action, its receptors widely distributed nerves, islets, heart, lung, skin, organs. Several animal experiments trials demonstrated GLP-1R more effective treating preventing obesity. Therefore, promising agents for individuals. This review describes evidence research on We anticipate this will generate data biomedical researchers workers develop obesity treatments based agonists.

Язык: Английский

Процитировано

136
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment DOI Creative Commons
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li

и другие.

Pharmacological Research, Год журнала: 2022, Номер 186, С. 106550 - 106550

Опубликована: Ноя. 11, 2022

Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's (PD). However, neuroinflammatory pathways have yet to be effectively targeted in clinical treatments for diseases. Interestingly, increased inflammation risk been associated with type 2 diabetes mellitus (T2DM) insulin resistance (IR), suggesting that mitigate T2DM pathology may successful treating well. Glucagon-like peptide-1 (GLP-1) an incretin hormone promotes healthy signaling, regulates blood sugar levels, suppresses appetite. Consequently, numerous GLP-1 receptor (GLP-1R) stimulating drugs developed approved by the US Food Drug Administration (FDA) related global regulatory authorities treatment T2DM. Furthermore, GLP-1R anti-inflammatory, neurotrophic, neuroprotective properties disorder preclinical models, hence hold promise repurposing In this review, we discuss pathways, intersections between neuroinflammation, brain IR, diseases, focus on AD PD. We additionally overview current FDA-approved agents development, including unimolecular single, dual, triple agonists, highlight those trials treatment. propose already-approved agonists safe, efficacious, cost-effective strategy ameliorating PD quelling neuroinflammation.

Язык: Английский

Процитировано

130
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases DOI
Sofie Hædersdal, Andreas Andersen, Filip K. Knop

и другие.

Nature Reviews Endocrinology, Год журнала: 2023, Номер 19(6), С. 321 - 335

Опубликована: Март 17, 2023

Язык: Английский

Процитировано

80
Gut hormone co-agonists for the treatment of obesity: from bench to bedside DOI
Rubén Nogueiras, Michael A. Nauck,

Matthias H. Tschöp

и другие.

Nature Metabolism, Год журнала: 2023, Номер 5(6), С. 933 - 944

Опубликована: Июнь 12, 2023

Язык: Английский

Процитировано

65
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy DOI Creative Commons

Matthias H. Tschöp,

Rubén Nogueiras, Bo Åhrén

и другие.

Diabetologia, Год журнала: 2023, Номер 66(10), С. 1796 - 1808

Опубликована: Май 20, 2023

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical therapies for the treatment of type 2 diabetes and obesity. They mimic action GLP-1 to reduce glucose levels through stimulation insulin secretion inhibition glucagon secretion. also body weight by inducing satiety central actions. The used clinically based on exendin-4 native available as formulations daily or weekly s.c. oral administration. agonism is achieved inhibitors dipeptidyl peptidase-4 (DPP-4), which prevent inactivation glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their raised after meal ingestion. Other developments in include formation small orally compounds with potential pharmaceutically stimulate from gut. In addition, GLP-1/glucagon GLP-1/GIP dual GLP-1/GIP/glucagon triple have shown blood effects islets peripheral tissues, improving beta cell function stimulating energy expenditure. This review summarises gut hormone-based presents future outlook use Graphical

Язык: Английский

Процитировано

53
Transforming obesity: The advancement of multi-receptor drugs DOI

Christine M. Kusminski,

Diego Pérez–Tilve, Timo D. Müller

и другие.

Cell, Год журнала: 2024, Номер 187(15), С. 3829 - 3853

Опубликована: Июль 1, 2024

Язык: Английский

Процитировано

31
Futile cycles: Emerging utility from apparent futility DOI Creative Commons
Anand K. Sharma, Radhika Khandelwal, Christian Wolfrum

и другие.

Cell Metabolism, Год журнала: 2024, Номер 36(6), С. 1184 - 1203

Опубликована: Апрель 1, 2024

Futile cycles are biological phenomena where two opposing biochemical reactions run simultaneously, resulting in a net energy loss without appreciable productivity. Such state was presumed to be aberration and thus deemed an energy-wasting "futile" cycle. However, multiple pieces of evidence suggest that utilities emerge from futile cycles. A few established functions control metabolic sensitivity, modulate homeostasis, drive adaptive thermogenesis. Yet, the physiological regulation, implication, pathological relevance most remain poorly studied. In this review, we highlight abundance versatility propose classification scheme. We further discuss energetic implications various their impact on basal rate, bona fide tentative pathophysiological implications, putative drug interactions.

Язык: Английский

Процитировано

27
Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation DOI Creative Commons

Areesha Moiz,

Kristian B. Filion, Michael A. Tsoukas

и другие.

The American Journal of Medicine, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

4
Glucose-dependent insulinotropic polypeptide (GIP) DOI Creative Commons
Timo D. Müller, Alice E. Adriaenssens,

Bo Ahrén

и другие.

Molecular Metabolism, Год журнала: 2025, Номер 95, С. 102118 - 102118

Опубликована: Фев. 28, 2025

Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in maintenance of glucose tolerance healthy humans. Until recently GIP had not been developed as a therapeutic thus has overshadowed by other incretin, glucagon-like peptide 1 (GLP-1), which is basis for several successful drugs to treat diabetes obesity. However, there rekindling interest biology recent years, great part due pharmacology demonstrating that both GIPR agonism antagonism may be beneficial treating obesity diabetes. This apparent paradox reinvigorated field, led new lines investigation, deeper understanding GIP. In this review, we provide detailed overview on multifaceted nature discuss implications signal modification various diseases. Following its classification hormone, emerged pleiotropic hormone with variety metabolic effects outside endocrine pancreas. The numerous render interesting candidate development pharmacotherapies obesity, diabetes, drug-induced nausea bone neurodegenerative disorders.

Язык: Английский

Процитировано

4